Comparative Pharmacology
Head-to-head clinical analysis: PERTZYE versus ZENPEP.
Head-to-head clinical analysis: PERTZYE versus ZENPEP.
PERTZYE vs ZENPEP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pancreatic enzyme replacement therapy: provides lipase, amylase, and protease to digest fats, carbohydrates, and proteins in the duodenum, compensating for deficient exocrine pancreatic secretion.
ZenPep (pancrelipase) is a pancreatic enzyme replacement therapy containing lipase, protease, and amylase. It hydrolyzes fats to monoglycerides, glycerol, and fatty acids; proteins to amino acids and peptides; and starch to dextrins and short-chain sugars, thereby facilitating digestion in patients with exocrine pancreatic insufficiency.
500 to 2500 lipase units/kg per meal orally, with snacks at 50% of meal dose; maximum 2500 lipase units/kg per meal or 10,000 lipase units/kg/day.
500 lipase units/kg per meal orally, with snacks at half the meal dose; maximum 2500 lipase units/kg per meal or 10,000 lipase units/kg per day.
None Documented
None Documented
Not applicable; PERTZYE is not absorbed systemically and does not exhibit a systemic half-life. Its activity is confined to the gut lumen.
Not applicable; ZenPep is not absorbed systemically and has no measurable plasma half-life. Clinical effect is directly related to local enzyme activity in the duodenum.
PERTZYE (pancrelipase) is not absorbed systemically; it acts locally in the gastrointestinal tract. After oral administration, the enzymes are degraded and excreted primarily in feces as inactive metabolites. No significant renal or biliary elimination occurs.
ZenPep (pancrelipase) is not absorbed systemically; it acts locally in the gastrointestinal tract. No significant systemic absorption occurs; therefore, excretion is primarily fecal as unabsorbed enzymes and degradation products. Renal excretion is negligible.
Category C
Category C
Pancreatic Enzyme Replacement
Pancreatic Enzyme Replacement